"Efficacy and Safety of a Monoclonal Purified Factor VIII Concentrate: 5-year Follow-Up in Previously Treated HIV-Negative Haemophiliacs."

According to the authors' abstract of an article published in Haemostasis, "The efficacy and safety of a monoclonal purified factor VIII concentrate (Hemofil M) were assessed in a historically controlled study in 22 HIV-negative patients with haemophilia A, previously treated with various concentrates. Data from 5 years of follow-up were compared with those from the preceding 6 months. Factor VIII consumption remained unchanged. A temporary increase in the number of reported bleedings was attributed to more frequent follow-up visits in the first year. Allergic reactions, inhibitor formation and HIV infection were not seen. Liver function parameters fluctuated in individual patients,...

Want to see the full article?

• Purchase this article for only $3.00